JP2003523735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003523735A5 JP2003523735A5 JP2001538509A JP2001538509A JP2003523735A5 JP 2003523735 A5 JP2003523735 A5 JP 2003523735A5 JP 2001538509 A JP2001538509 A JP 2001538509A JP 2001538509 A JP2001538509 A JP 2001538509A JP 2003523735 A5 JP2003523735 A5 JP 2003523735A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated
- seq
- antibody
- cells
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 description 23
- 238000000034 method Methods 0.000 description 18
- 239000012634 fragment Substances 0.000 description 16
- 239000012472 biological sample Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 12
- 210000004408 hybridoma Anatomy 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 3
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 1
- 102000027581 NK cell receptors Human genes 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44051499A | 1999-11-15 | 1999-11-15 | |
| CA2,288,307 | 1999-11-15 | ||
| CA2288307A CA2288307C (en) | 1999-11-15 | 1999-11-15 | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
| US09/440,514 | 1999-11-15 | ||
| PCT/EP2000/011697 WO2001036630A2 (en) | 1999-11-15 | 2000-11-15 | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003523735A JP2003523735A (ja) | 2003-08-12 |
| JP2003523735A5 true JP2003523735A5 (enExample) | 2008-01-17 |
| JP4776845B2 JP4776845B2 (ja) | 2011-09-21 |
Family
ID=25681295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538509A Expired - Fee Related JP4776845B2 (ja) | 1999-11-15 | 2000-11-15 | ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1240326B1 (enExample) |
| JP (1) | JP4776845B2 (enExample) |
| AT (1) | ATE423848T1 (enExample) |
| AU (1) | AU783899B2 (enExample) |
| DE (1) | DE60041655D1 (enExample) |
| DK (1) | DK1240326T3 (enExample) |
| ES (1) | ES2321687T3 (enExample) |
| WO (1) | WO2001036630A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10261223A1 (de) * | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| WO2004056392A1 (en) * | 2002-12-23 | 2004-07-08 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
| EP1445614A1 (en) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method for the in vitro assessment of the progression status of an HIV virus in an invidual |
| CA2532547C (en) | 2003-07-24 | 2020-02-25 | Innate Pharma | Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds |
| EP1740618A1 (en) * | 2004-04-30 | 2007-01-10 | Innate Pharma | Compositions and methods for enhancing nk cell activity |
| RU2395294C2 (ru) * | 2004-06-18 | 2010-07-27 | Дженентек, Инк. | Способы применения агонистов аро-2l-рецепторов и активаторов nk-клеток |
| EP1773884B1 (en) | 2004-08-03 | 2012-03-07 | Innate Pharma | Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor |
| EP1626059A1 (en) * | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| PT1831258E (pt) | 2004-12-28 | 2016-01-07 | Univ Genova | Anticorpos monoclonais contra nkg2a |
| EP2322557B1 (en) | 2005-10-14 | 2017-08-30 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| ES2629440T5 (es) * | 2007-10-04 | 2020-11-20 | Zymogenetics Inc | zB7H6 miembro de la familia B7 y composiciones y métodos relacionados |
| CA2990520C (en) * | 2015-07-24 | 2023-06-27 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| CA3079363A1 (en) | 2017-11-21 | 2019-05-31 | Innate Pharma | Multispecific antigen binding proteins |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| CA3166629A1 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| JP2023109240A (ja) * | 2022-01-27 | 2023-08-08 | 学校法人 東洋大学 | ナチュラルキラー細胞活性の測定方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69430846T2 (de) * | 1993-08-27 | 2003-01-16 | Dana-Farber Cancer Institute, Boston | Für natürliche killerzellen spezifische antigene und sie identifizierende antikörper |
| WO1999023867A2 (en) * | 1997-11-07 | 1999-05-20 | Biogen, Inc. | Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use |
| WO1999049881A2 (de) * | 1998-03-27 | 1999-10-07 | Gabriele Multhoff | Verwendung von hsp70 protein |
-
2000
- 2000-11-15 WO PCT/EP2000/011697 patent/WO2001036630A2/en not_active Ceased
- 2000-11-15 ES ES00989877T patent/ES2321687T3/es not_active Expired - Lifetime
- 2000-11-15 DK DK00989877T patent/DK1240326T3/da active
- 2000-11-15 JP JP2001538509A patent/JP4776845B2/ja not_active Expired - Fee Related
- 2000-11-15 AU AU26677/01A patent/AU783899B2/en not_active Ceased
- 2000-11-15 AT AT00989877T patent/ATE423848T1/de active
- 2000-11-15 DE DE60041655T patent/DE60041655D1/de not_active Expired - Lifetime
- 2000-11-15 EP EP00989877A patent/EP1240326B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003523735A5 (enExample) | ||
| DE69325577T2 (de) | Mn-gen und protein | |
| JPH09505723A (ja) | ４３ｋｄヒトガン抗原からの免疫反応性ペプチド配列 | |
| JP2007532139A5 (enExample) | ||
| EP1012292A1 (en) | Ntn-2 member of tnf ligand family | |
| JP4776845B2 (ja) | ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体 | |
| US6979546B2 (en) | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same | |
| KR20080059449A (ko) | 치료용 약제 | |
| JP2025131589A (ja) | 固形腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 | |
| JP2003525566A (ja) | １２５個のヒト分泌タンパク質 | |
| US8071716B2 (en) | Thymus-specific protein | |
| JP2000083688A (ja) | ＩＬ―１ファミリ―の新規メンバ―、ＩＬ―１δ | |
| US20070148686A1 (en) | Protein present at the surface of hematopoietic stem cells of the lymphoid line and of nk cells, and uses thereof | |
| JP2023526218A (ja) | 生体高分子標的特異的補体阻害剤及びその製造方法と応用 | |
| JP3231262B2 (ja) | ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体 | |
| CA2104997A1 (en) | Bone-related cadherin-like protein and process for its production | |
| JP3924330B2 (ja) | 新規タンパク質、その遺伝子、アポトーシス誘導用試薬及び抗ガン剤 | |
| WO1998029448A1 (en) | Human pathogenesis-related protein | |
| JP2000515726A (ja) | 分泌蛋白をコードする成人ｐｂｍｃ由来のポリヌクレオチド | |
| TW202306971A (zh) | 用於治療視神經脊髓炎之肽及方法 | |
| JP2002504361A (ja) | ３６個のヒト分泌タンパク質 | |
| US20250228951A1 (en) | Novel-peptide-based anticancer immunotherapeutic agent | |
| KR102689877B1 (ko) | CD300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 | |
| JPH03502446A (ja) | 動物およびヒトのレクチン類の少なくとも一部分の配列を再現するアミノ酸配列，それを得る方法，およびその診断および治療への用途 | |
| CA2288307C (en) | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |